Top

Journal of Mammary Gland Biology and Neoplasia

Published in:

01-12-2012 | Preface

Editorial

Author: Marc Lippman

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 3-4/2012

Excerpt

It is a pleasure to provide a brief introduction to this special issue of the Journal of Mammary Gland Biology and Neoplasia devoted to Novel Molecular Targets in Breast Cancer. This issue contains reviews on several targets that have been selected because, in our opinion, they represent areas in which basic science has advanced to the point at which innovative and validating clinical trials can be accomplished. Much of this work is built on a substantial body of prior work and success that it is worth very briefly recapitulating. …

DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:408–18.CrossRef

Early Breast Cancer Trialists’ Collaborative Group E. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012;379:432–44.

Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA. International Union of Pharmacology LXIV Estrogen receptors. Pharmacol Rev. 2006;58:773–81.PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

Jordan VC. Chemoprevention of breast cancer with selective oestrogen receptor modulators. Nat Rev Cancer. 2007;7:46–53.PubMedCrossRef

Krop I, Beeram M, Modi S, et al. A phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698–704.PubMedCrossRef

Reis-Filho J, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–23.PubMedCrossRef

Title: Editorial
Author: Marc Lippman
Publication date: 01-12-2012
Publisher: Springer US
Published in: Journal of Mammary Gland Biology and Neoplasia / Issue 3-4/2012
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-012-9270-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3-4/2012

Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer

Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy

Translating Mathematical Modeling of Tumor Growth Patterns into Novel Therapeutic Approaches for Breast Cancer

Epigenetics as a Therapeutic Target in Breast Cancer

Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics

Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer